19 Aug Life Edit Therapeutics
Amy Pooler, Ph.D., Senior Vice President, Research and Development
Oct. 6 | 5:00pm | FLW Ballroom G
Durham, NC
(Private)
Life Edit is ElevateBio’s next-generation gene editing and R&D technology business, offering one of the world’s largest and most diverse libraries of RNA-guided nucleases (RGNs), base editors, and reverse transcriptase (RT) editors that provide flexible editing and unprecedented access to the genome. The Life Edit gene editing platform is available to make the entire spectrum of edits – from small insertions or deletions to rewriting sections of DNA – to lead the genetic medicine revolution in ex vivo and in vivo therapeutic development to treat and potentially cure disease. These technologies can be commercialized through various partnership structures, ranging from exclusive licensing and R&D collaborations to technology democratization deals. Each technology is also integrated within ElevateBio’s ecosystem, enabling the Company to discover, develop, manufacture, and commercialize an unprecedented, broad spectrum of cell and gene therapies.
